Your browser doesn't support javascript.
loading
The efficacy of anti-PD-1 agents in acral and mucosal melanoma.
Shoushtari, Alexander N; Munhoz, Rodrigo R; Kuk, Deborah; Ott, Patrick A; Johnson, Douglas B; Tsai, Katy K; Rapisuwon, Suthee; Eroglu, Zeynep; Sullivan, Ryan J; Luke, Jason J; Gangadhar, Tara C; Salama, April K S; Clark, Varina; Burias, Clare; Puzanov, Igor; Atkins, Michael B; Algazi, Alain P; Ribas, Antoni; Wolchok, Jedd D; Postow, Michael A.
Afiliación
  • Shoushtari AN; Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center, New York, New York. shoushta@mskcc.org.
  • Munhoz RR; Weill Cornell Medical College, New York, New York. shoushta@mskcc.org.
  • Kuk D; Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Ott PA; Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Johnson DB; Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
  • Tsai KK; Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee.
  • Rapisuwon S; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.
  • Eroglu Z; Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia.
  • Sullivan RJ; Moffitt Cancer Center, Tampa, Florida.
  • Luke JJ; Massachussetts General Hospital, Harvard Medical School, Boston, Massachusetts.
  • Gangadhar TC; University of Chicago Comprehensive Cancer Center Chicago, Illinois.
  • Salama AK; Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania.
  • Clark V; Duke University School of Medicine, Durham, North Carolina.
  • Burias C; Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Puzanov I; Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center, New York, New York.
  • Atkins MB; Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, Tennessee.
  • Algazi AP; Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia.
  • Ribas A; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California.
  • Wolchok JD; Jonsson Comprehensive Cancer Center, University of California at Los Angeles, Los Angeles, California.
  • Postow MA; Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center, New York, New York.
Cancer ; 122(21): 3354-3362, 2016 Nov 15.
Article en En | MEDLINE | ID: mdl-27533633
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Neoplasias Encefálicas / Protocolos de Quimioterapia Combinada Antineoplásica / Receptor de Muerte Celular Programada 1 / Neoplasias Hepáticas / Melanoma / Membrana Mucosa Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Año: 2016 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Neoplasias Encefálicas / Protocolos de Quimioterapia Combinada Antineoplásica / Receptor de Muerte Celular Programada 1 / Neoplasias Hepáticas / Melanoma / Membrana Mucosa Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adult / Aged / Aged80 / Female / Humans / Male / Middle aged Idioma: En Revista: Cancer Año: 2016 Tipo del documento: Article